Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

被引：0
|
作者：
Mostaghimi, Arash [1 ]
Mesinkovska, Natasha Atanaskova [2 ]
Senna, Maryanne Makredes [3 ]
King, Brett [4 ]
Hamilton, Colleen [5 ]
Cassella, James [5 ]
机构：
[1] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA
[2] Univ Calif Irvine, Clin Res, Irvine, CA USA
[3] Lahey Hosp & Med Ctr, Hair Loss Ctr Excellence, Burlington, MA USA
[4] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA
[5] Concert Pharmaceut, Lexington, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42752
引用
收藏
页码：AB164 / AB164
页数：1
相关论文
共 7 条
  • [1] Patient Reported Outcomes in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
    Mesinkovska, Natasha Atanaskova
    Senna, Maryanne Makredes
    Mostaghimi, Arash
    King, Brett
    Hamilton, Colleen
    Cassella, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB204 - AB204
  • [2] Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
    King, Brett
    Mesinkovska, Natasha Atanaskova
    Senna, Maryanne Makredes
    Mostaghimi, Arash
    Hamilton, Colleen
    Cassella, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [3] Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
    Senna, Maryanne Makredes
    King, Brett
    Mesinkovska, Natasha Atanaskova
    Mostaghimi, Arash
    Hamilton, Colleen
    Cassella, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB43 - AB43
  • [4] Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata
    King, Brett
    Mesinkovska, Natasha
    Mirmirani, Paradi
    Bruce, Suzanne
    Kempers, Steve
    Guttman-Yassky, Emma
    Roberts, Janet L.
    McMichael, Amy
    Colavincenzo, Maria
    Hamilton, Colleen
    Braman, Virginia
    Cassella, James, V
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 306 - 313
  • [5] Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
    Zlotogorski, Abraham
    Vano-Galvan, Sergio
    Piraccini, Bianca Maria
    Durand, Frederick
    Yu, Guanglei
    Chiasserini, Chiara
    Lu, Na
    Mostaghimi, Arash
    JEADV CLINICAL PRACTICE, 2024,
  • [6] Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
    Senna, Maryanne M.
    McMichael, Amy J.
    Mayo, Tiffany T.
    Mackay-Wiggan, Julian
    Glashofer, Marc
    Sun, Luna
    Yu, Guanglei
    Nunes, Fabio P.
    McCollam, Jill S.
    Wu, Wen-Shuo
    King, Brett
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB85 - AB85
  • [7] Concordance between clinician- reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVEAA1 and BRAVE-AA2 studies
    Mostaghimi, Arash
    Ko, Justin
    Tosti, Antonella
    McMichael, Amy
    Ohyama, Manabu
    Ito, Taisuke
    Dutronc, Yves
    Ball, Susan
    Yu, Guanglei
    Murage, Mwangi
    Chen, Yun-Fei
    Chiasserini, Chiara
    Wollenberg, Andreas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 729 - 732
1